{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:38:45Z","timestamp":1790793525662,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1918,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/jto.0b013e3181e981d9","type":"journal-article","created":{"date-parts":[[2010,8,26]],"date-time":"2010-08-26T11:56:08Z","timestamp":1282823768000},"page":"1477-1480","source":"Crossref","is-referenced-by-count":45,"title":["Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"5","author":[{"given":"Annemarie","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atie","family":"van Wijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter E.","family":"Postmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181e981d9_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181e981d9_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181e981d9_bib3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2009-0055","article-title":"Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK","volume":"14","author":"Thatcher","year":"2009","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e3181e981d9_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Galimont-Collen","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3181e981d9_bib5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1097\/JTO.0b013e3181e981d9_bib6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1468-3083.2009.03516.x","article-title":"Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia","volume":"24","author":"Eames","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1097\/JTO.0b013e3181e981d9_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2008.19.7236","article-title":"Small molecule tyrosine kinase inhibitor and depression","volume":"10","author":"Quek","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181e981d9_bib8","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/JTO.0b013e3181bbb2b9","article-title":"Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity","volume":"4","author":"Lind","year":"2009","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415306286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415306286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T23:08:39Z","timestamp":1591830519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415306286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S1556086415306286"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181e981d9","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}